Reduces the phosphorylation of checkpoint proteins, such as structural maintenance of chromosome 1, checkpoint kinase 1, and p53 in DOX‐treated ataxia telangiectasia mutated in a dose‐dependent manner. This evidence concerns the gene TP53 and Ataxia-telangiectasia.